Results 121 to 130 of about 53,609 (266)

Final Efficacy and Safety Results of Pyrotinib Combined With Trastuzumab and Chemotherapy in Pre‐Treated Human Epidermal Growth Factor Receptor 2‐Positive Metastatic Breast Cancer

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Purpose Findings from our previous study showed that the combination of pyrotinib, trastuzumab, and chemotherapy represents a viable treatment strategy with an acceptable safety profile for heavily pre‐treated human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer (MBC).
Xiaofeng Xie, Daijia Huang, Jiayi Huang, Xuelian Chen, Xue Bai, Wenyu Zheng, Liping Chen, Xiaofeng Lan, Lin Song, Rongmei Lei, Caiwen Du   +10 more
wiley   +1 more source

c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma [PDF]

, 1989
Manoochehr Tavassoli, Philip Quirke, Farzin Farzaneh, NJ Lock, LV Mayne, N Kirkham   +5 more
openalex   +1 more source

Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcomes of dacomitinib as a first‐line treatment in patients
Ping‐Chih Hsu, How‐Wen Ko, Li‐Chung Chiu, Shih‐Hao Huang, Chung‐Shu Lee, Yu‐Ching Lin, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Chin‐Chou Wang, Cheng‐Ta Yang   +9 more
wiley   +1 more source

C－erbB－2表达对乳腺浸润性导管癌预后的预测

Zhongshan Daxue xuebao. Yixue kexue ban, 1996
应用单克隆抗体Ｃ－ｅｒｂＢ－２肿瘤蛋白及免疫组化（ＬＳＡＢ）法，对８４例乳腺浸润性导管癌作Ｃ－ｅｒｂＢ－２癌基因蛋白产物表达（简称Ｃ－ｅｒｂＢ－２表达）检测并与随诊资料进行比较分析，结果（１）Ｃ－ｅｒｂＢ－２在本组病例的表达率为５５．９％（４７／８４）。（２）Ｃ－ｅｒｂＢ－２表达与肿瘤的ＴＮＭ分期、复发／远必转移、５ａ生存率无相关性（Ｐ＞０．０５）、而仅与腋淋巴结转移状况和２ａ死亡率有关（Ｐ＜０．００５及Ｐ＜０．０５）。（３）有／无淋巴结转移病例的Ｃ－ｅｒｂＢ－２表达与患者的预后均无关（Ｐ＞０．７５ ...
doaj  

Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3 [PDF]

, 1996
Rafael Molina, Judith Jo, Gabriel Zanón, Xavier Filella, B. Farrús, Montserrat Muñoz-Mateu, M L Latre, Jaume Pahisa, M Velasco, P Fernandez, Jordi Vilà, Ballesta Am   +11 more
openalex   +1 more source

Non‐HLA Risk Loci ERBB3/IKZF4 and ERBB2/IKZF3/GSDMB/ORMDL3 Interact to Influence Progression of Autoimmunity in Relatives of T1D Patients

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 3, March 2026.
ABSTRACT Aim The genetic loci, ERBB2/IKZF3/GSDMB/ORMDL3 on chromosome 17q, and ERBB3/IKZF4 on chromosome 12q represent confirmed non‐HLA risk factors for the development of autoimmunity and progression to type 1 diabetes (T1D). It is unknown whether both regions can interact to influence the progression of T1D.
Ina M. Mertens, Bart Keymeulen, Frans K. Gorus, Mark Van De Casteele, the Belgian Diabetes Registry   +4 more
wiley   +1 more source

上皮钙黏蛋白及C-erbB-2在非小细胞肺癌中的表达及意义

Zhongguo shiyan zhenduanxue, 2012
目的探讨上皮钙黏蛋白（E-cad、β-cat）和C-erbB-2在非小细胞肺癌（NSCLC）中的表达及其相互之间的关系。方法免疫组化SP法检测了41例非小细胞肺癌标本中E-cad、β-cat、C-erbB-2的表达情况。结果 E-cad及β-cat在NSCLC中低表达,并与临床分期、病理分级及淋巴结转移有明显相关性 ...
王凤玲, 隋小芳, 杨永清, 陈尚君   +3 more
doaj  

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

Prognostic and clinical implications of c-erbB-2 expression in patients with oral cancer: A meta-analysis. [PDF]

Medicine (Baltimore), 2020
Meng Y, Yang P, Ma L.
europepmc   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source